Leerink Partnrs Has Pessimistic View of GPCR Q4 Earnings

Key Points

• Leerink Partners has revised its Q4 2025 EPS forecast for Structure Therapeutics, lowering it from $2.58 to $2.51, while the company recently reported a loss of ($0.36) per share for Q2, missing consensus estimates.
• A number of brokerages have set varying price targets for Structure Therapeutics, with an average target of $75.71 and a consensus rating of "Buy" from eight research analysts.
• Currently, 91.78% of Structure Therapeutics' stock is owned by institutional investors and hedge funds, indicating strong institutional confidence in the company.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Stock analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for shares of Structure Therapeutics in a research report issued to clients and investors on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $2.51 for the quarter, down from their prior estimate of $2.58. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share.

GPCR has been the subject of several other reports. Guggenheim reduced their price target on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, June 23rd. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. Citigroup started coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Finally, HC Wainwright lowered their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded up $1.23 during trading on Friday, hitting $18.74. 1,074,532 shares of the stock traded hands, compared to its average volume of 875,744. The stock has a market cap of $1.08 billion, a P/E ratio of -17.95 and a beta of -1.89. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $45.37. The company has a fifty day moving average price of $19.70 and a two-hundred day moving average price of $21.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

Institutional Trading of Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. LPL Financial LLC boosted its stake in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares in the last quarter. Geode Capital Management LLC boosted its stake in Structure Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock worth $1,240,000 after purchasing an additional 480 shares in the last quarter. Trexquant Investment LP boosted its stake in Structure Therapeutics by 592.0% in the fourth quarter. Trexquant Investment LP now owns 52,876 shares of the company's stock worth $1,434,000 after purchasing an additional 45,235 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Structure Therapeutics by 202.5% in the fourth quarter. Wells Fargo & Company MN now owns 10,103 shares of the company's stock worth $274,000 after purchasing an additional 6,763 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after purchasing an additional 843 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.